Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

Overview of attention for article published in HEPAC Health Economics in Prevention and Care, October 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 69 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison

Article in European Journal of Cancer (November 2023)

Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil

Article in Journal of Medical Economics (May 2023)

The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price

Article in Value in Health (January 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.